Adherence to Hydroxyurea Therapy in Children with Sickle Cell Anemia

Journal of Pediatrics

Volumn 156, Issue 3, 2010, Pages 415-419

  Thornburg, Courtney D ^a   Calatroni, Agustin ^b   Telen, Marilyn ^a   Kemper, Alex R ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RHO INC   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CHILD; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SICKLE CELL ANEMIA; SPLENOMEGALY; VISUAL ANALOG SCALE;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ATTITUDE; CHILD; CHILD, PRESCHOOL; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBINS; HUMANS; HYDROXYUREA; LEUKOCYTE COUNT; MALE; MEDICATION ADHERENCE; PAIN MEASUREMENT; PARENTS;

EID: 76749158307     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.09.044     Document Type: Article

References (23)

1. Zimmerman S.A., Schultz W.H., Davis J.S., Pickens C.V., Mortier N.A., Howard T.A., et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103 (2004) 2039-2045
2. Hankins J.S., Ware R.E., Rogers Z.R., Wynn L.W., Lane P.A., Scott J.P., et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106 (2005) 2269-2275
3. Brawley O.W., Cornelius L.J., Edwards L.R., Gamble V.N., Green B.L., Inturrisi C., et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 148 (2008) 932-938
4. Elliott V., Morgan S., Day S., Mollerup L.S., and Wang W. Parental health beliefs and compliance with prophylactic penicillin administration in children with sickle cell disease. J Pediatr Hematol Oncol 23 (2001) 112-116
5. Day S., Brunson G., and Wang W. A successful education program for parents of infants with newly diagnosed sickle cell disease. J Pediatr Nurs 7 (1992) 52-57
6. Barakat L.P., Lutz M., Smith-Whitley K., and Ohene-Frempong K. Is treatment adherence associated with better quality of life in children with sickle cell disease?. Qual Life Res 14 (2005) 407-414
7. Treadwell M.J., Law A.W., Sung J., Hackney-Stephens E., Quirolo K., Murray E., et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 44 (2005) 500-507
8. Olivieri N.F., and Vichinsky E.P. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 20 (1998) 26-31
9. de Montalembert M., Brousse V., Elie C., Bernaudin F., Shi J., and Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91 (2006) 125-128
10. Heeney M.M., and Ware R.E. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 55 (2008) 483-501
11. Morisky D.E., Green L.W., and Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24 (1986) 67-74
12. Haynes R.B., and Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 8 (1987) 12-19
13. R: A language and environment for statistical computing. In. http://cran.r-project.org/doc/manuals/refman.pdf. Accessed October 13, 2009.
14. Thornburg C.D., Dixon N., Burgett S., Mortier N.A., Schultz W.H., Zimmerman S.A., et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 52 (2009) 609-615
15. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94 (1999) 1550-1554
16. Zimmerman S.A., Schultz W.H., Burgett S., Mortier N.A., and Ware R.E. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110 (2007) 1043-1047
17. Ware R.E., Zimmerman S.A., and Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94 (1999) 3022-3026
18. Ware R.E., Zimmerman S.A., Sylvestre P.B., Mortier N.A., Davis J.S., Treem W.R., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145 (2004) 346-352
19. Heeney M.M., Whorton M.R., Howard T.A., Johnson C.A., and Ware R.E. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 26 (2004) 179-184
20. Treadwell M.J., and Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol 38 (2001) 77-84
21. Berkovitch M., Papadouris D., Shaw D., Onuaha N., Dias C., and Olivieri N.F. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol 45 (1998) 605-607
22. Patik M., Phillips L., Kladny B., Captain A., Gettig E., and Krishnamurti L. Structured telephone-based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. Am J Hematol 81 (2006) 462-464
23. Davis H. Use of computerized health claims data to monitor compliance with antibiotic prophylaxis in sickle cell disease. Pharmacoepidemiol Drug Saf 7 (1998) 107-112